Cisplatin and gemcitabine in non-small-cell lung cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 5, 1999, Pages

  Cartei, G ^a   Sacco, C ^a   Sibau, A ^a   Pella, N ^a   Iop, A ^a   Tabaro, G ^a  

^a Operative Unit of Medical Oncology   (Italy)

Author keywords

Gemcitabine; Gemcitabine cisplatin; Non small cell lung cancer

Indexed keywords

CISPLATIN; GEMCITABINE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0032692350     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_5.S57     Document Type: Conference Paper

References (47)

1. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899-909.
2. Cartei G, Cartei F, Cantone A et al. Cisplatin cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 794-800.
3. Ginsberg RJ, Kris MG, Armstrong JG. Non-small-cell lung cancer. In DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology, third edition. Philadelphia: Lippincott 1993; 23: 673-723.
4. Liguori S, Tabaro G, Cartei G et al. Mitomycin-C in non-small-cell lung cancer therapy. Third International Congress on Cancer: 'Chemotherapy of non-small-cell lung cancer: New achievements', Venice, 29-31 May 1998; 21 (Abstr Book, Abstr 10).
5. Sandler AJ, Nemunaitis J, Dehanam C et al. Phase III study of cisplatin with or without gemcitabine in patients with advanced non-small-cell lung cancer. Proc ASCO 1998; 17: 454a.
6. Cartei G, Rosa Bian R, Cendron P et al. Evaluation of synergy with cis-platinum in non-small-cell lung cancer: Interim report from a multicentric study. Proc ASCO 1988; 7: 198.
7. Minna JD, Higgins GA, Glatstein EJ. Cancer of the lung. In DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology, first edition. Philadelphia: Lippincott 1982; 14: 396-474.
8. Minna JD, Higgins GA, Glatstein EJ. Cancer of the lung. In DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology, second edition. Philadelphia: Lippincott 1985; 18: 507-97.
9. Ginsberg RJ, Vokes EE, Raben A. Non-small-cell lung cancer. In DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer - Principles and Practice of Oncology, fifth edition. Philadelphia: Lippincott-Raven 1997: 30: 858-911.
10. Kern DH, Morgan CR, Hildebrand-Zanki SU. In vitro pharmacodynamics of 1-D-arabinofuranosylcytosine: Synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res 1988; 48: 117-21.
11. Swinnen LJ, Barnes DM. Fisher SG et al. 1-D-arabinofuranosyl-cytosine and hydroxyurea: Production of cytotoxic synergy with cis-diamminedichloro-platinum(II) and modifications in platinum-induced DNA interstrand crosslinking. Cancer Res 1989; 49: 1383-9.
12. Hertel LW, BoderGB, Kroin JS et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′deoxycytidine). Cancer Res 1990; 50: 4417-22.
13. Ruiz van Haperen VWT, Veerman G, Vermorken JB et al. 2′,2′-difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines. Biochem Pharmacol 1993: 46: 762-6.
14. Eli-Lilly, data on file Eli-Lilly Co, Indianapolis, IN.
15. Green MR. Gemcitabine safety overview. In Gemcitabine Briefing. Adelphi Mill, Bollington, Macclesfield, Cheshire, UK: Adelphi Communications Ltd: 12-3.
16. Tonato M, Mosconi AM, Martin C. Safety profile of gemcitabine. Anti-Cancer Drugs 1995; 6: 27-32.
17. Cortes-Funes H, Martin C, Abratt R, Lund B. Safely profile of gemcitabine, a novel anticancer agent, in non-small-cell lung cancer. Anti-Cancer Drugs 1997; 8: 582-7.
18. Parkinson DR, Pluda JM, Cazenave L et al. Investigational anticancer agents. In Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy, 2nd edition. Philadephia: Lippincott-Raven 1996; 22; 509-27.
19. Shepherd FA. Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small-cell lung cancer: An overview. Anti-Cancer Drugs 1995; 6: 19-25.
20. Mosconi AM, Crinò L, Tonato M. Combination therapy with gemcitabine in non-small-cell lung cancer. Eur J Cancer 1997; 33: S14-7.
21. Abbruzzese JL. Phase I studies of the novel anticancer agent Gemcitabine. In Recent Clinical Advances with Gemzar (Gemcitabine HCL). Eli Lilly Oncology 1996; 3: 2-6.
22. Reed E, Dabholkar M. Chabner BA. Platinum analogues. In Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy, 2nd edition. Philadelphia: Lippincott-Raven 1996; 14: 357-78.
23. Zamble DM, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995; 20: 435-9.
24. Braakhius BJM, Ruiz van Haperen VWT, Bergman AM et al. Preclinical in vivo evaluation of the combination of 2,3-difluorodeoxycytidine (dFdC, gemcitabine) and cisplatin (CDDP). Ann Oncol 1994; 5: 82-6.
25. Peters GJ, Bergman AM, Ruiz van Haperen VWTet al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22: 72-9.
26. Plunkett W. Huang P. Searcy CE et al. Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23: 3-15.
27. Abratt RP, Bezwoda WR. Goedhals L et al. Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 1997; 15: 744-9.
28. Yang L-Y, Li L, Liu L et al. Gemcitabine suppresses the repair of cisplatin adducts in plasmid DNA by extracts of cisplatin-resistant human colon carcinoma cells. Proc AACR 1995; 36: 357a.
29. neul. Cancer Res 1996; 56: 794-801.
30. Scagliotti GV, Crino L. Combination studies of gemcitabine and cisplatin in advanced non-small-cell lung cancer. In Recent Clinical Advances with Gemzar (Gemcitabine HCl). Eli Lilly Oncology 1996; 3: 19-23.
31. Valeriote FA, Edelstein MB. The role of cell kinetics in cancer chemotherapy. Semin Oncol 1997; 4: 217-26.
32. Steward WP, Dunlop DJ, Dabouis G et al. Phase I-II study of gemcitabine and cisplatin in the treatment of advanced non-small-cell lung cancer: Preliminary results. Semin Oncol 1996; 23: 43-7.
33. Crinò L, Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1997; 15: 297-303.
34. Shepherd FA, Cormier Y, Burkes R et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small-cell lung cancer. Semin Oncol 1997; 24: 27-30.
35. Isla D, Cajal A, Mayordomo JI et al. Results of treatment with cisplatin + gemcitabine in advanced non-small-cell lung cancer. Paris, France: Eight International Congress on Anti-Cancer Treatment, 3-6 February 1998; Abstr P271.
36. Anton A, Artal A, Carrato A et al. Gemcitabine plus cisplatin in advanced NSCLC: Final phase II results. Proc ASCO 1997;16: 1656a.
37. Gonzales-Baron M, Gracia M, Gracia Giron C et al. Phase II activity of gemcitabine + cisplatin in advanced non-small-cell lung cancer. Eigth World Conference of Lung Cancer, 10-15 August 1997, Dublin, Ireland; Abstr 67.
38. Einhorn L. Phase II trial of gemcitabine plus cisplatin in non-small-cell lung cancer: A Hoosier Oncology Group Study. Semin Oncol 1997; 24: 24-30.
39. Lopez Cabrerizo MP, Cardenal F, Arial A et al. Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small-cell lung cancer: A randomized trial by the Spanish lung cancer group. Eight World Conference of Lung Cancer, 10-15 August 1997, Dublin, Ireland (Abstr 27).
40. Crinò L, Conte P, De Marinis F et al. A randomised trial of gemcitabine and cisplatin (GP) versus mitomicyn, ifosfamide and cisplatin in advanced non-small-cell lung cancer: A multicentric phase III study. Proc ASCO 1998; 17: 455a.
41. Rinaldi M, Crinò L, Scagliotti G et al. A new schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: A phase II randomized trials. Proc ASCO 1998; 17: 470a.
42. van Zandwijk N, Crinò L, Kramer GWet al. Phase II study with gemcitabine plus Cisplatin as induction regimen for patients with stage III non-small-cell lung cancer by EORTC Lung Cooperative Group (EORTC 08955). Proc ASCO Proc 1998; 17: 468a.
43. Cartei G, Sacco C. Cioschi B et al. Gemcitabine and platin in non-small-cell lung cancer. A phase II study with emphasis on intention-to-treat analysis. Proc ASCO 1998; 17: 467a.
44. Comella P, Panza N, Frasci G et al. Gemcitabine-cisplatin-vinorelbine combination in advanced non-small-cell lung cancer. A phase II randomized study. Proc ASCO 1997; 16: 449a.
45. Tonato M, Crinò L, Mosconi AM. Rationale of a phase III study comparing a standard cisplatin regimen with cisplatin and gemcitabine in non-small-cell lung cancer. Semin Oncol 1997; 24: 31-5.
46. Eastern Cooperative Oncology Group. A randomized phase III trial in metastatic non-small-cell lung cancer. ECOG Meeting Agenda 1996; 482.
47. Vokes EE, Leopold KA, Herndorn JE et al. A CALGB randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy in stage IIIB non-small-cell lung cancer: Feasibility data. Proc ASCO 1997; 16: 455a.